Analyst Predicts 16-Year Highs for Churning Drug Stock

One upbeat analyst is calling SRPT a key small- to mid-cap stock pick for 2018

Dec 27, 2017 at 9:49 AM
facebook twitter linkedin

Oppenheimer analyst Hartaj Singh weighed in bullishly today on Sarepta Therapeutics Inc (NASDAQ:SRPT), calling the biopharmaceutical stock "a key SMID-cap pick in our coverage universe." In a note to clients, Singh said, "We do not see any meaningful competition to SRPT’s [Duchenne muscular dystrophy] franchise for another 3-5 years," and reiterated both his "outperform" rating and a $76 price target on the shares.

It's been a blowout year for Sarepta stock, with the drugmaker's shares more than doubling in value over the course of 2017. SRPT has been consolidating some gains just below $57 since early November, but support from its rising 50-day moving average remains firmly intact. Out of the gate this morning, the security isn't showing any immediate signs of breaking out above its short-term ceiling; SRPT is just fractionally higher at $56.70.

Singh's price target, meanwhile, stands about 35% north of current levels, and in territory the stock hasn't touched since January 2002. It's a somewhat loftier target than the consensus, as SRPT's average 12-month price target checks in at $69.47.

However, bullish analyst ratings are nothing new for the stock. Among the 15 brokerage firms tracking SRPT, no fewer than 14 call it a "buy" or "strong buy," with just a single "hold" rounding out the ratings.

Sarepta Therapeutics has yet to win over the shorts, though. Short interest rose by 29.2% over the past two reporting periods, and now accounts for 23.5% of the stock's float. At SRPT's average daily trading volume, it would take 8.4 days for all of these shorted shares to be covered.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners